Synthesis and Potent In vitro Activity of Novel 1H-Benzimidazoles as Anti-MRSA Agents

Chemical Biology and Drug Design

Volumn 80, Issue 2, 2012, Pages 237-244

  Karataş, Hacer ^a   Alp, Mehmet ^a   Yildiz, Sulhiye ^a   Göker, Hakan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

1H Benzimidazole; Antifungal and antibacterial activities; Benzamide; Benzamidine; Methicillin resistant Staphylococcus aureus

Indexed keywords

1 (4 CHLOROBENZYL) 2 (3,4 DICHLOROPHENYL) N [3 IMINO 3 (BUTYLAMINO) 3 IMINOPROPYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 1 (4 CHLOROBENZYL) 2 (3,4 DICHLOROPHENYL) N [3 IMINO 3 [(1 METHYLETHYL)AMINO]PROPYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 1 BUTYL 2 (3,4 DICHLOROPHENYL) N [2 (1,4,5,6 TETRAHYDROPYRIMIDIN 2 YL)ETHYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 1 BUTYL 2 (3,4 DICHLOROPHENYL) N [3 IMINO 3 [(1 METHYLETHYL)AMINO]PROPYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 1 BUTYL 2 (3,4 DICHLOROPHENYL) N [3 IMINO 3 [(3 METHYLBUTYL)AMINO]PROPYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 2 (3,4 DICHLOROPHENYL) N [2 (1,4,5,6 TETRAHYDROPYRIMIDIN 2 YL)ETHYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 2 (3,4 DICHLOROPHENYL) N [3 IMINO 3 [(1 METHYLETHYL)AMINO]PROPYL] 1H BENZIMIDAZOLE 5 CARBOXAMIDE; 3 (1 BENZYL 5,6 DICHLORO 1H BENZIMIDAZOL 2 YL) N (2 ETHYLAMINOETHYL)BENZAMIDE; 3 (5,6 DICHLORO 1 NAPHTHALEN 1 YLMETHYL 1H BENZIMIDAZOL 2 YL) N (2 ETHYLAMINOETHYL)BENZAMIDE; 3 [5,6 DICHLORO 1 (4 CHLOROBENZYL) 1H BENZIMIDAZOL 2 YL] N (2 DIMETHYLAMINOETHYL)BENZAMIDE; 3 [5,6 DICHLORO 1 (4 CHLOROBENZYL) 1H BENZIMIDAZOL 2 YL] N (2 ETHYLAMINOETHYL)BENZAMIDE; 3 [5,6 DICHLORO 1 (4 CHLOROBENZYL) 1H BENZIMIDAZOL 2 YL] N (2 ISOPROPYLAMINOETHYL)BENZAMIDE; AMPICILLIN; ANTIINFECTIVE AGENT; BENZIMIDAZOLE DERIVATIVE; FLUCONAZOLE; N (3 AMINO 3 IMINOPROPYL) 2 (3,4 DICHLOROPHENYL) 1H BENZIMIDAZOLE 5 CARBOXAMIDE; N (3,4 DICHLOROBENZYL) 4 [5,6 DICHLORO 1 (4 CHLOROBENZYL) 1H BENZIMIDAZOL 2 YL]BENZAMIDINE; N (4 CHLOROBENZYL) 4 [5,6 DICHLORO 1 (4 CHLOROBENZYL) 1H BENZIMIDAZOL 2 YL]BENZAMIDINE; SULTAMICILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BENZIMIDAZOLES; CANDIDA; CANDIDIASIS; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84864005566     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01393.x     Document Type: Article

References (21)

1. Styers D., Sheehan D.J., Hogan P., Sahm D.F. (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob;5:2.
2. Wiselka M. (2004) Recently introduced antibiotics: a guide for the general physician. Clin Med;4:494-498.
3. Fauci A.S., Touchette N.A., Folkers G.K. (2005) Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis;11:519-525.
4. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. (2006) Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet;368:874-885.
5. Lundstrom T.S., Sobel J.D. (2004) Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infect Dis Clin North Am;18:651-668.
6. Hutchinson D.K. (2003) Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem;3:1021-1042.
7. Gravestock M.B. (2005) Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Devel;8:469-477.
8. Shah P.M. (2005) The need for new therapeutic agents: what is in the pipeline? Clin Microbiol Infect;11(Suppl. 3):36-42.
9. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., Robbins M. (2003) Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother;51:186-188.
10. Özden S., Karataş H., Yildiz S., Göker H. (2004) Synthesis and potent antimicrobial activity of some novel 4-(5, 6-dichloro-1H-benzimidazol-2-yl)-N-substituted benzamides. Arch Pharm (Weinheim);337:556-562.
11. Göker H., Tebrizli E., Abbasoglu U. (1996) Synthesis of 1, 2-disubstituted benzimidazole-5(6)-carboxamides and evaluation of their antimicrobial activity. Farmaco;51:53-58.
12. Göker H., Özden S., Yildiz S., Boykin D.W. (2005) Synthesis and potent antibacterial activity against MRSA of some novel 1, 2-disubstituted-1H-benzimidazole-N-alkylated-5-carboxamidines. Eur J Med Chem;40:1062-1069.
13. Seth P.P., Jefferson E.A., Risen L.M., Osgood S.A. (2003) Identification of 2-amino-benzimidazole dimers as antibacterial agents. Bioorg Med Chem Lett;13:1669-1672.
14. Hu L., Kully M.L., Boykin D.W., Abood N. (2009) Synthesis and in vitro activity of dicationic bis-benzimidazoles as a new class of anti-MRSA and anti-VRE agents. Bioorg Med Chem Lett;19:1292-1295.
15. Hu L., Kully M.L., Boykin D.W., Abood N. (2009) Synthesis and structure-activity relationship of dicationic diaryl ethers as novel potent anti-MRSA and anti-VRE agents. Bioorg Med Chem Lett;19:4626-4629.
16. Weidner-Wells M.A., Ohemeng K.A., Nguyen V.N., Fraga-Spano S., Macielag M.J., Werblood H.M., Foleno B.D., Webb G.C., Barrett J.F., Hlasta D.J. (2001) Amidino benzimidazole inhibitors of bacterial two-component systems. Bioorg Med Chem Lett;11:1545-1548.
17. Del Poeta M., Schell W.A., Dykstra C.C., Jones S.K., Tidwell R.R., Kumar A., Boykin D.W., Perfect J.R. (1998) In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles, Antimicrob. Agents Chemother;42:2503-2510.
18. Arslan B., Kazak C., Karatas H., Özden S. (2004) Methyl 1-n-butyl-2-(3, 4-dichlorophenyl)-1H-benzimidazole-5-carboxylate. Acta Cryst;E60:o1535-o1537.
19. Seth P.P., Robinson D.E., Jefferson E.A., Swayze E.E. (2002) Efficient solution phase synthesis of 2-(N-acyl)-aminobenzimidazoles. Tetrahedron Lett;43:7303-7306.
20. National Committee for Clinical Laboratory Standards. (2000) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th edn. 17(2), Approve Standard M7-A5. Wayne, PA: NCCLS.
21. Shadomy S., Pfaller M.A. (1991) Laboratory studies with antifungal agents: susceptibility tests and quantitation in bodyfluids. In: Balows A., Hausler W.J., Hermann K.L., Isenberg H.D., Shadomy H.J., editors. Manual of Clinical Microbiology, 5th edn. Washington DC, USA: American Society of Microbiology; Chapter 117, p. 1173.